How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/relapsed-or-refractory-multiple-myeloma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Relapsed or refractory multiple myeloma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Relapsed or refractory multiple myeloma (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Relapsed or refractory multiple myeloma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Pf-07248144	pf-07248144	Pfizer	Small molecule inhibitor	Specific protein involved in disease pathways	Not available
Pf-07293893	pf-07293893	Pfizer	JAK inhibitor	Janus kinase (JAK) pathway	Not available
Lynozyfic	LINVOSELTAMAB	Rengeneron Pharmaceuticals, Inc.	Bispecific B Cell Maturation Antigen-directed CD3 T Cell Engager [EPC]		2025-01-01
Elrexfio	elranatamab-bcmm	Pfizer		Tumor necrosis factor receptor superfamily member 17	2023-01-01
Elrexfio	elranatamab	Pfizer	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
Talvey	TALQUETAMAB	Janssen Biotech		T-cell surface glycoprotein CD3	2023-01-01
Bcmaxcd3	TECLISTAMAB	Johnson & Johnson		CD3, BCMA	2022-01-01
Pepaxto	MELPHALAN FLUFENAMIDE	Oncopeptides Ab	Alkylating Drug		2021-01-01
Pf-07264660	pf-07264660	Pfizer	Unknown	Unknown
Pf-04171327	pf-04171327	Pfizer	Selective glucocorticoid receptor modulator (SGRM)	Glucocorticoid receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 13 drugs in Relapsed or refractory multiple myeloma
JANSSEN BIOTECH · 2 drugs in Relapsed or refractory multiple myeloma
Johnson & Johnson · 1 drug in Relapsed or refractory multiple myeloma
Oncopeptides Ab · 1 drug in Relapsed or refractory multiple myeloma
Rengeneron Pharmaceuticals, Inc. · 1 drug in Relapsed or refractory multiple myeloma
Oncopeptides AB · 1 drug in Relapsed or refractory multiple myeloma
Janssen Biotech · 1 drug in Relapsed or refractory multiple myeloma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Relapsed or refractory multiple myeloma:

Cite this brief

Drug Landscape (2026). Relapsed or refractory multiple myeloma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/relapsed-or-refractory-multiple-myeloma. Accessed 2026-06-10.

Relapsed or refractory multiple myeloma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing